Opportunities for Small Molecules in Cancer Immunotherapy

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.

Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212 · see citing works

The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells

Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145 · see citing works

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · see citing works

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · see citing works

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · see citing works

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917 · see citing works

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585 · see citing works

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · see citing works

Immunological effects of conventional chemotherapy and targeted anticancer agents

Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · see citing works

Adaptive immunity maintains occult cancer in an equilibrium state

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,438 · see citing works

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · see citing works

Therapeutic cancer vaccines

Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works

A2A adenosine receptor protects tumors from antitumor T cells

Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D. E., Wong, M. K. K., Huang, X., Caldwell, S. A., Liu, K., Smith, P. T., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,066 · see citing works

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · see citing works

Design of amidobenzimidazole STING receptor agonists with systemic activity

Ramanjulu, J. M., Pesiridis, G. S., Yang, J., Concha, N., Singhaus, R., Zhang, S.-Y., Tran, J.-L., Moore, P., Lehmann, S., Eberl, H. C., et al. (2018) · Nature · doi:10.1038/s41586-018-0705-y · Cited by 912 · see citing works

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., de Vijver, K. K. V., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 912 · see citing works

Cytokine patterns in patients with cancer: a systematic review

Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 906 · see citing works

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P. J., Upstill‐Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 850 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors

Lou, Y., McDonald, P. C., Oloumi, A., Chia, S., Ostlund, C., Ahmadi, A., Kyle, A. H., Keller, U. A. D., Leung, S., Huntsman, D. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4261 · Cited by 761 · see citing works

Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH

Chiche, J., Ilc, K., Laferrière, J., Trottier, E., Dayan, F., Mazure, N. M., Brahimi-Horn, M. C., & Pouysségur, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2470 · Cited by 751 · see citing works

The clinical role of the TME in solid cancer

Giraldo, N. A., Sánchez-Salas, R., Peske, J. D., Vano, Y. A., Becht, É., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 738 · see citing works

Immunogenicity of somatic mutations in human gastrointestinal cancers

Tran, E., Ahmadzadeh, M., Lu, Y.-C., Gros, A., Turcotte, S., Robbins, P. F., Gartner, J. J., Zheng, Z., Li, Y. F., Ray, S., et al. (2015) · Science · doi:10.1126/science.aad1253 · Cited by 729 · see citing works

Small‐Molecule PROTACS: New Approaches to Protein Degradation

Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674 · see citing works

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

Molon, B., Ugel, S., Pozzo, F. D., Soldani, C., Zilio, S., Avella, D., Palma, A. D., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 651 · see citing works

Nuclear cGAS suppresses DNA repair and promotes tumorigenesis

Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0629-6 · Cited by 651 · see citing works

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23373 · Cited by 637 · see citing works

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 556 · see citing works

Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs

Li, L., Yin, Q., Kuss, P., Maliga, Z., Millán, J. L., Wu, H., & Mitchison, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1661 · Cited by 537 · see citing works

Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation

Liu, Y., Liang, X., Dong, W., Fang, Y., Lv, J., Zhang, T., Fiskesund, R., Xie, J., Liu, J., Yin, X., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.005 · Cited by 535 · see citing works

Characterization of a Subset of the Basic-Helix-Loop-Helix-PAS Superfamily That Interacts with Components of the Dioxin Signaling Pathway

Hogenesch, J. B., Chan, W. K., Jackiw, V., Brown, R. C., Gu, Y.-Z., Pray-Grant, M. G., Perdew, G. H., & Bradfield, C. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8581 · Cited by 514 · see citing works

Regulation of T Cell Receptor CD3ζ Chain Expression byl-Arginine

Rodrı́guez, P. C., Zea, A. H., Culotta, K. S., Zabaleta, J., Ochoa, J. B., & Ochoa, A. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110675200 · Cited by 512 · see citing works

Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment

Steggerda, S. M., Bennett, M. K., Chen, J., Emberley, E. D., Huang, T. C., Janes, J. R., Li, W., MacKinnon, A. L., Makkouk, A., Marguier, G. M., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0308-4 · Cited by 488 · see citing works

Recent advances in arginine metabolism: roles and regulation of the arginases

Morris Jr, S. M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00278.x · Cited by 485 · see citing works

Big opportunities for small molecules in immuno-oncology

Adams, J. L., Smothers, J. F., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 482 · see citing works

CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis

Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477 · see citing works

CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice

Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451 · see citing works

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma

Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448 · see citing works

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Żak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A. S. S., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 443 · see citing works

IDO1 in cancer: a Gemini of immune checkpoints

Zhai, L., Ladomersky, E., Lenzen, A. C., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 441 · see citing works

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer

Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416 · see citing works

Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies

Liston, D. R., & Davis, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3083 · Cited by 400 · see citing works

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Uy, G. L., Rettig, M. P., Motabi, I., McFarland, K., Trinkaus, K. M., Hladnik, L. M., Kulkarni, S., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., et al. (2012) · Blood · doi:10.1182/blood-2011-10-383406 · Cited by 399 · see citing works

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M. M., & Sitkovsky, M. V. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398 · see citing works

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma

Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393 · see citing works

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

Guzik, K., Żak, K. M., Grudnik, P., Magiera‐Mularz, K., Musielak, B., Törner, R., Skalniak, Ł., Dömling, A. S. S., Dubin, G., & Holak, T. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00293 · Cited by 380 · see citing works

TLR agonists: our best frenemy in cancer immunotherapy

Kaczanowska, S., Joseph, A. M., & Dávila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 340 · see citing works

STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation

Lemos, H. D. P., Mohamed, E. T., Huang, L., Ou, R., Pacholczyk, G. A., Arbab, A. S., Munn, D. H., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325 · see citing works

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Karzai, F. H., VanderWeele, D. J., Madan, R. A., Owens, H., Cordes, L. M., Hankin, A., Couvillon, A., Nichols, E. H., Bilušić, M., Beshiri, M. L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0463-2 · Cited by 310 · see citing works

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

Santo, C. D., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Soldato, P. D., Melani, C. C., Guiducci, C., Colombo, M. P., Iezzi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409783102 · Cited by 284 · see citing works

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy

Zhou, W., Guo, S., Liu, M., Burow, M. E., & Wang, G. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170830111531 · Cited by 279 · see citing works

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 274 · see citing works

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Smith, M. M., García-Martínez, E., Pitter, M. R., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 232 · see citing works

The paradox of Th17 cell functions in tumor immunity

Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., Mahdian-shakib, A., Jadidi‐Niaragh, F., Azizi, G., & Baradaran, B. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.015 · Cited by 218 · see citing works

Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules

Yang, J., & Hu, L. (2018) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 198 · see citing works

Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model

Dubois, L. J., Lieuwes, N. G., Maresca, A., Thiry, A., Supuran, C. T., Scozzafava, A., Wouters, B. G., & Lambin, P. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.019 · Cited by 195 · see citing works

Cyclooxygenase‐2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy

Pang, L. Y., Hurst, E. A., & Argyle, D. J. (2016) · Stem Cells International · doi:10.1155/2016/2048731 · Cited by 194 · see citing works

STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer

Ghaffari, A., Peterson, N. T., Khalaj, K., Vitkin, N., Robinson, A. G., Francis, J., & Koti, M. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0188-5 · Cited by 188 · see citing works

PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

Ruf, M., Moch, H., & Schraml, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.30077 · Cited by 179 · see citing works

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174 · see citing works

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance

Hennequart, M., Pilotte, L., Canè, S., Hoffmann, D., Stroobant, V., Plaen, E. D., & den Eynde, B. J. V. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0400 · Cited by 171 · see citing works

In vitroandin vivocharacterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist

af Forselles, K., Root, J. A., Clarke, T. L., Davey, D. A., Aughton, K., Dack, K. N., & Pullen, N. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01495.x · Cited by 164 · see citing works

Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies

Huck, B. R., Kötzner, L., & Urbahns, K. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707816 · Cited by 149 · see citing works

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells

Nejad, E. B., van der Sluis, T. C., van Duikeren, S., Yagita∥, H., Janssen, G. M. C., van Veelen, P. A., Melief, C. J. M., van der Burg, S. H., & Arens, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0881 · Cited by 137 · see citing works

Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells

Onoue, T., Uchida, D., Begum, N., Tomizuka, Y., Yoshida, H., & Sato, M. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.5.1133 · Cited by 134 · see citing works

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors

Ganesan, A., Ahmed, M., Okoye, I., Arutyunova, E. I., Babu, D., Turnbull, W. L., Kundu, J. K., Shields, J. A., Agopsowicz, K. C., Xu, L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48826-6 · Cited by 134 · see citing works

Priming anti-tumor immunity by radiotherapy: Dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells

Krombach, J., Hennel, R., Brix, N., Orth, M., Schötz, U., Ernst, A., Schuster, J., Zuchtriegel, G., Reichel, C. A., Bierschenk, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1523097 · Cited by 132 · see citing works

The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves

Kerr, W. G., & Chisholm, J. D. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800991 · Cited by 131 · see citing works

Clinical pharmacology considerations for the development of immune checkpoint inhibitors

Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124 · see citing works

A chemical approach for global protein knockdown from mice to non-human primates

Sun, X., Wang, J., Yao, X., Zheng, W., Mao, Y., Lan, T., Wang, L., Sun, Y., Zhang, X., Zhao, Q., et al. (2019) · Cell Discovery · doi:10.1038/s41421-018-0079-1 · Cited by 118 · see citing works

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

Ferris, R. L., Saba, N. F., Gitlitz, B. J., Haddad, R. I., Sukari, A. W., Neupane, P. C., Morris, J. C., Misiukiewicz, K. J., Bauman, J. E., Fenton, M. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1888 · Cited by 113 · see citing works

Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines

Gillespie, R. J., Bamford, S. J., Botting, R., Comer, M., Denny, S., Gaur, S., Griffin, M., Jordan, A. M., Knight, A. R., Lerpiniere, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800961g · Cited by 104 · see citing works

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

Hu, X., Liu, X., Moisan, J., Wang, Y., Lesch, C. A., Spooner, C. J., Morgan, R. W., Zawidzka, E. M., Mertz, D. R., Bousley, D., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1254854 · Cited by 104 · see citing works

CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion

Zhu, H., Gu, Y., Xue, Y., Yuan, M., Cao, X., & Liu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.23020 · Cited by 102 · see citing works

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

Ma, X., Holt, D. M., Kundu, N., Reader, J. C., Goloubeva, O. G., Take, Y., & Fulton, A. M. (2013) · OncoImmunology · doi:10.4161/onci.22647 · Cited by 99 · see citing works

Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma

Orecchioni, S., Talarico, G., Labanca, V., Calleri, A., Mancuso, P., & Bertolini, F. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0076-z · Cited by 98 · see citing works

Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates

Zom, G. G., Khan, S., Britten, C. M., Sommandas, V., Camps, M. G. M., Loof, N. M., Budden, C. F., Meeuwenoord, N. J., Filippov, D. V., van der Marel, G. A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0223 · Cited by 97 · see citing works

Dynamic Structural Differences between Human and Mouse STING Lead to Differing Sensitivity to DMXAA

Shih, A. Y., Damm‐Ganamet, K. L., & Mirzadegan, T. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2017.10.027 · Cited by 87 · see citing works

Pembrolizumab plus Chemotherapy in Lung Cancer

Gil-Sierra, M. D., Fenix-Caballero, S., & Rey, E. J. A. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmc1808567 · Cited by 87 · see citing works

Imidazopyridine- and Purine-Thioacetamide Derivatives: Potent Inhibitors of Nucleotide Pyrophosphatase/Phosphodiesterase 1 (NPP1)

Chang, L., Lee, S.-Y., Leonczak, P., Rozenski, J., Jonghe, S. D., Hanck, T., Müller, C. E., & Herdewijn, P. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501434y · Cited by 86 · see citing works

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals

Shayan, G., Kansy, B., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J. P., Kim, S., Duvvuri, U., Clump, D. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 83 · see citing works

Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion

Wang, J., Bhatia, A., Cleveland, N. K., Gupta, N., Dalal, S. R., Rubin, D. T., & Sakuraba, A. (2018) · ACG Case Reports Journal · doi:10.14309/crj.2018.56 · Cited by 75 · see citing works

Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations

Watt, G. F., Scott‐Stevens, P., & Gaohua, L. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.02.005 · Cited by 72 · see citing works

Ah Receptor Antagonism Represses Head and Neck Tumor Cell Aggressive Phenotype

DiNatale, B. C., Smith, K. M., John, K., Gowda, K., Amin, S., & Perdew, G. H. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0216 · Cited by 71 · see citing works

Discovery of [cis-3-({(5R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist

Kono, M., Ochida, A., Oda, T., Imada, T., Banno, Y., Taya, N., Masada, S., Kawamoto, T., Yonemori, K., Nara, Y., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00061 · Cited by 71 · see citing works

Specific MHC-I Peptides Are Induced Using PROTACs

Jensen, S. M., Potts, G. K., Ready, D. B., & Patterson, M. J. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02697 · Cited by 69 · see citing works

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity

Dietsch, G. N., Lu, H., Yang, Y., Morishima, C., Chow, L. Q. M., Disis, M. L., & Hershberg, R. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148764 · Cited by 67 · see citing works

Targeting pattern-recognition receptors to discover new small molecule immune modulators

Zhu, G., Xu, Y., Cen, X., Nandakumar, K. S., Liu, S., & Cheng, K. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.026 · Cited by 66 · see citing works

CXCR4 regulates migration of lung alveolar epithelial cells through activation of Rac1 and matrix metalloproteinase-2

Ghosh, M. C., Makena, P. S., Gorantla, V. K., Sinclair, S. E., & Waters, C. M. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00321.2011 · Cited by 65 · see citing works

New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors

Ciccarese, C., Alfieri, S., Santoni, M., Santini, D., Brunelli, M., Bergamini, C., Licitra, L. F., Montironi, R., Tortora, G., & Massari, F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1120287 · Cited by 62 · see citing works

CXCR4 antagonists suppress small cell lung cancer progression

Taromi, S., Kayser, G., Catusse, J., von Elverfeldt, D., Reichardt, W., Braun, F., Weber, W., Zeiser, R., & Burger, M. (2016) · Oncotarget · doi:10.18632/oncotarget.13238 · Cited by 62 · see citing works

Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities

Zhang, L. J., Dewan, V., & Yin, H. H. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00419 · Cited by 61 · see citing works

Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment

Miao, J., Xu, L., Hu, Y., Piao, C., Wu, X., Liu, X., Huang, C., Wang, Y., Li, D., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21155 · Cited by 61 · see citing works

Synthetic RORγt Agonists Enhance Protective Immunity

Chang, M. R., Dharmarajan, V., Doebelin, C., Garcia-Ordoñez, R. D., Novick, S. J., Kuruvilla, D. S., Kamenecka, T. M., & Griffin, P. R. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00899 · Cited by 58 · see citing works

Directing the Immune System with Chemical Compounds

Mancini, R. J., Stutts, L., Ryu, K. A., Tom, J. K., & Esser-Kahn, A. P. (2014) · ACS Chemical Biology · doi:10.1021/cb500079s · Cited by 57 · see citing works

Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients

Lee, M.-H., Chang, J. T., Liao, C., Chen, Y.-S., Kuo, M., & Shen, C. (2018) · Oncotarget · doi:10.18632/oncotarget.23934 · Cited by 53 · see citing works

Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells

Radvák, P., Repic, M., Švastová, E., Takáčová, M., Csáderová, L., Strnad, H., Pastorek, J., Pastoreková, S., & Kopáček, J. (2013) · Oncology Reports · doi:10.3892/or.2013.2226 · Cited by 50 · see citing works

Prostaglandin EP2 receptor: Novel therapeutic target for human cancers (Review)

Sun, X., & Li, Q. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3744 · Cited by 46 · see citing works

Identification of Hepatic Niche Harboring Human Acute Lymphoblastic Leukemic Cells via the SDF-1/CXCR4 Axis

Kato, I., Niwa, A., Heike, T., Fujino, H., Saito, M. K., Umeda, K., Hiramatsu, H., Ito, M., Morita, M., Nishinaka, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027042 · Cited by 42 · see citing works

Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies

Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z., & Debets, R. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.004 · Cited by 42 · see citing works

Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer

Tang, H., Liu, Y., Wang, C., Zheng, H., Chen, Y., Liu, W., Chen, X., Zhang, J., Chen, H., Yang, Y., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.254359 · Cited by 41 · see citing works

Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer

Wang, R., Yang, L., Zhang, C., Wang, R., Zhang, Z., He, Q., Chen, X., Zhang, B., Qin, Z., Wang, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461303 · Cited by 40 · see citing works

Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode

Fujimoto, J., Kurasawa, O., Takagi, T., Liu, X., Banno, H., Kojima, T., Asano, Y., Nakamura, A., Nambu, T., Hata, A., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00400 · Cited by 40 · see citing works

Design, synthesis, and biological evaluation of C7-functionalized DMXAA derivatives as potential human-STING agonists

Hwang, J., Kang, T., Lee, J. H., Choi, B., & Han, S. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob01798k · Cited by 37 · see citing works

Dual Synthetic Peptide Conjugate Vaccine Simultaneously Triggers TLR2 and NOD2 and Activates Human Dendritic Cells

Zom, G. G., Willems, M. M. J. H. P., Meeuwenoord, N. J., Reintjens, N. R. M., Tondini, E., Khan, S., Overkleeft, H. S., van der Marel, G. A., Codée, J. D. C., OSSENDORP, F. A., et al. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00087 · Cited by 34 · see citing works

Carboranyl Analogues of Celecoxib with Potent Cytostatic Activity against Human Melanoma and Colon Cancer Cell Lines

Buzharevski, A., Paskaš, S., Sárosi, M. B., Laube, M., Lönnecke, P., Neumann, W., Mijatović, S., Maksimović‐Ivanić, D., Pietzsch, J., & Hey‐Hawkins, E. (2019) · ChemMedChem · doi:10.1002/cmdc.201800685 · Cited by 33 · see citing works

Therapeutic Potential of Small Molecule Inhibitors

Khera, N., & Rajput, S. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25782 · Cited by 32 · see citing works

Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5′-P α,α -Dithiophosphate Analogues

Zelikman, V., Pelletier, J., Simhaev, L., Sela, A., Gendron, F., Arguin, G., Senderowitz, H., Sévigny, J., & Fischer, B. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01906 · Cited by 32 · see citing works

Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study

Naing, A., Powderly, J. D., Falchook, G. S., Creelan, B., Nemunaitis, J. J., Lutzky, J., Diab, A. K., Wang, J. S.-Z., Laing, N. M., Niewood, M., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct177 · Cited by 26 · see citing works

Chemotherapy oxaliplatin sensitizes prostate cancer to immune checkpoint blockade therapies via stimulating tumor immunogenicity

Zhou, J., Yang, T., Liu, L., & Lu, B. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6908 · Cited by 23 · see citing works

Companies Scaling Back IDO1 Inhibitor Trials

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-nd2018-007 · Cited by 21 · see citing works

IDO-GCN2 and autophagy in inflammation

McGaha, T. L. (2015) · Oncotarget · doi:10.18632/oncotarget.4846 · Cited by 20 · see citing works

Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

Li, N., Li, H., Su, F., Li, J., Ma, X., & Gong, P. (2015) · PubMed Central · Cited by 20 · see citing works

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

Successes and challenges in clinical gene therapy

Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 199 · see citing works

Drug combination therapy for emerging viral diseases

Shyr, Z. A., Cheng, Y., Lo, D. C., & Zheng, W. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.008 · Cited by 191 · see citing works

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-Immunotherapy in Multiple Solid Tumors

Mei, K.-C., Liao, Y.-P., Jiang, J., Chiang, M., Khazaieli, M., Liu, X.-S., Wang, X., Liu, Q., Chang, C., Zhang, X., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c05194 · Cited by 139 · see citing works

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations

Gilad, Y., Gellerman, G., Lonard, D. M., & O’Malley, B. W. (2021) · Cancers · doi:10.3390/cancers13040669 · Cited by 146 · see citing works

Small molecule-based immunomodulators for cancer therapy

Wu, Y., Yang, Z., Cheng, K., Bi, H., & Chen, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.007 · Cited by 112 · see citing works

Epigenetic state determines the in vivo efficacy of STING agonist therapy

Falahat, R., Berglund, A., Perez-Villarroel, P., Putney, R. M., Hamaidi, I., Kim, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2023) · Nature Communications · doi:10.1038/s41467-023-37217-1 · Cited by 94 · see citing works

Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy

Chen, Y., Zhi, S., Ou, J., Gao, J., Zheng, L., Huang, M., Du, S., Shi, L., Tu, Y., & Cheng, K. (2023) · ACS Nano · doi:10.1021/acsnano.3c02724 · Cited by 86 · see citing works

Maximizing response to intratumoral immunotherapy in mice by tuning local retention

Momin, N., Palmeri, J. R., Lutz, E. A., Jailkhani, N., Mak, H. H., Tabet, A., Chinn, M. M., Kang, B. H., Spanoudaki, V. C., Hynes, R. O., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27390-6 · Cited by 81 · see citing works

Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells

Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 71 · see citing works

Light‐Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy

Choi, J., Park, B., Park, J. Y., Shin, D., Lee, S., Yoon, H. Y., Kim, K., Kim, S. H., Kim, Y., Yang, Y., et al. (2024) · Advanced Materials · doi:10.1002/adma.202405475 · Cited by 71 · see citing works

Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3

Chung, Y. M., Khan, P. P., Wang, H., Tsai, W.-B., Qiao, Y., Yu, B., Larrick, J. W., & Hu, M. C. ‐. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002772 · Cited by 66 · see citing works

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

Vara, B., Levi, S. M., Achab, A., Candito, D. A., Fradera, X., Lesburg, C. A., Kawamura, S., Lacey, B. M., Lim, J., Methot, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00096 · Cited by 65 · see citing works

Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo

Ouyang, Y., Gao, J., Zhao, L., Lu, J., Zhong, H., Tang, H., Jin, S., Lü, Y., Li, Y., Guo, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00370 · Cited by 58 · see citing works

STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer

Shi, J., Liu, C., Luo, S., Cao, T., Lin, B., Zhou, M., Zhang, X., Wang, S., Zheng, T., & Li, X. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104384 · Cited by 51 · see citing works

Microfluidic technologies for immunotherapy studies on solid tumours

Paterson, K., Zanivan, S. R., Glasspool, R. M., Coffelt, S. B., & Zagnoni, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01305f · Cited by 48 · see citing works

Cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs); where do they stand in tumorigenesis and how they can change the face of cancer therapy?

Tajaldini, M., Saeedi, M., Amiriani, T., Amiriani, A., Sedighi, S., Zadeh, F. M., Dehghan, M. H., Jahanshahi, M., Zanjan, M. G., Khalili, P., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175087 · Cited by 46 · see citing works

Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives

Çeçen, B., Karavasili, C., Nazir, M., Bhusal, A., Dogan, E., Shahriyari, F., Tamburacı, S., Büyüköz, M., Kozacı, L. D., & Miri, A. K. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101657 · Cited by 37 · see citing works

Self‐Degradable Nanogels Reshape Immunosuppressive Tumor Microenvironment via Drug Repurposing Strategy to Reactivate Cytotoxic CD8+ T Cells

Tian, H., Li, W., Wang, G., Tian, Y., Yan, J., Zhou, S., Yu, X., Li, B., & Dai, Y. (2023) · Advanced Science · doi:10.1002/advs.202301661 · Cited by 34 · see citing works

Hydrogels for Engineering the Immune System

Li, X., Shou, Y., & Tay, A. K. P. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000073 · Cited by 34 · see citing works

Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer

Li, X., Yang, S., Zhang, H., Liu, X., Gao, Y., Chen, Y., Liu, L., Wang, D., Liang, Z., Liu, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01444 · Cited by 32 · see citing works

Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

Singh, S., Barik, D., Arukha, A. P., Prasad, S., Mohapatra, I., Singh, A. R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102621 · Cited by 31 · see citing works

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens

Darrigrand, R., Pierson, A., Rouillon, M., Renko, D. Z., Boulpicante, M., Bouyssié, D., Mouton‐Barbosa, E., Marcoux, J., Garcia, C., Ghosh, M., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01801-2 · Cited by 28 · see citing works

Transforming Cold Tumors into Hot Ones with a Metal–Organic Framework-Based Biomimetic Nanosystem for Enhanced Immunotherapy

Xu, M., Chang, Y., Zhu, G., Zhu, X., Song, X., & Li, J. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c21005 · Cited by 30 · see citing works

Localized delivery of immunotherapeutics: A rising trend in the field

Wang, J., Zhang, Y., Pi, J., Xing, D., & Wang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.013 · Cited by 29 · see citing works

ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma

Zhang, Q., Li, S., Ren, J., He, X., Shi, H., Zhang, F., Li, H., & Tong, R. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.026 · Cited by 29 · see citing works

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works

Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors

Shi, H., Tang, H., Li, Y., Chen, D., Liu, T., Chen, Y., Wang, X., Chen, L., Wang, Y., Xie, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115064 · Cited by 27 · see citing works

The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches

Koumarianou, A. A., & Durán, J. (2021) · Cancers · doi:10.3390/cancers13030363 · Cited by 26 · see citing works

G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma

Lam, M. S. Y., Reales‐Calderón, J. A., Ow, J. R., Aw, J., Tan, D., Vijayakumar, R., Ceccarello, E., Tabaglio, T., Lim, Y. T., Chien, W. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36160-5 · Cited by 26 · see citing works

Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer

Wang, T., Wu, L., Wang, S., Shi, X., Liu, H., & Deng, W. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60451-0 · Cited by 25 · see citing works

Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines

Zhang, W., Zheng, X., Coghi, P. S., Chen, J.-H., Dong, B.-J., & Fan, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1438030 · Cited by 27 · see citing works

Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy

Han, C., Zhang, A., Liu, Z., Moore, C., & Fu, Y. (2020) · Oncogene · doi:10.1038/s41388-020-01575-7 · Cited by 22 · see citing works

Potential therapeutic uses of rexinoids

Leal, A. S., Reich, L. A., Moerland, J. A., Zhang, D., & Liby, K. T. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.01.004 · Cited by 24 · see citing works

Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses

Shi, J., Weng, J., & Mitchison, T. J. (2021) · eLife · doi:10.7554/elife.73673 · Cited by 23 · see citing works

Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs

Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189170 · Cited by 22 · see citing works

Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma

Ou, J., Zheng, L., Chen, Y., Fu, Q., Tan, L., Liang, E. Y., Huang, L., Pan, Y., Ke, J., Chen, Z., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01504 · Cited by 21 · see citing works

Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins

Dai, Z., Zhu, P.-F., Liu, H., Li, X., Zhu, Y.-Y., Liu, Y., Shi, X., Chen, W.-D., Liu, Y., Zhao, Y., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154335 · Cited by 20 · see citing works

Novel Siglec-15-Sia axis inhibitor leads to colorectal cancer cell death by targeting miR-6715b-3p and oncogenes

Ahmad, M. S., Braoudaki, M., Patel, H., Ahmad, I., Shagufta, S., & Siddiqui, S. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254911 · Cited by 20 · see citing works

Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid‐Based Nanoparticles

Fernandes, S., Cassani, M., Cavalieri, F., Forte, G., & Caruso, F. (2023) · Advanced Science · doi:10.1002/advs.202305769 · Cited by 20 · see citing works

Rational Design of Original Fused-Cycle Selective Inhibitors of Tryptophan 2,3-Dioxygenase

Kozlova, A., Thabault, L., Liberelle, M., Klaessens, S., Prévost, J. R. C., Mathieu, C., Pilotte, L., Stroobant, V., den Eynde, B. J. V., & Frédérick, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00323 · Cited by 20 · see citing works

Immune organoid for cancer immunotherapy

Wang, X., Wang, W., & Sun, Z. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.031 · Cited by 21 · see citing works

Structures/cytotoxicity/selectivity relationship of natural steroidal saponins against GSCs and primary mechanism of tribulosaponin A

Dai, Z., Liu, H., Wang, B., Yang, D., Zhu, Y.-Y., Yan, H., Zhu, P.-F., Liu, Y., Chen, H. C., Zhao, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113068 · Cited by 19 · see citing works

Discovery of novel N-sulfonamide-tetrahydroisoquinolines as potent retinoic acid receptor-related orphan receptor γt agonists

Ma, X., Sun, N., Li, X., & Fu, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113585 · Cited by 19 · see citing works

Discovery of ICOS‐Targeted Small Molecules Using Pharmacophore‐Based Screening

Calvo‐Barreiro, L., Talagayev, V., Pach, S., Abdel‐Rahman, S. A., Wolber, G., & Gabr, M. T. (2023) · ChemMedChem · doi:10.1002/cmdc.202300305 · Cited by 19 · see citing works

Design and synthesis of 1H-pyrazolo[3,4-d]pyrimidine derivatives as hematopoietic progenitor kinase 1 (HPK1) inhibitors

Zhang, J., Li, Y., Tang, H., Zhou, Q., Tong, L., Ding, J., Xie, H., Xiong, B., & Liu, T. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106811 · Cited by 17 · see citing works

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer

Leal, A. S., Moerland, J. A., Zhang, D., Carapellucci, S., Lockwood, B., Krieger-Burke, T., Aleiwi, B., Ellsworth, E. L., & Liby, K. T. (2021) · Cancers · doi:10.3390/cancers13195004 · Cited by 16 · see citing works

Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios

Verano, A. L., You, I., Donovan, K. A., Mageed, N., Yue, H., Nowak, R. P., Fischer, E. S., Wang, E. S., & Gray, N. S. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00439 · Cited by 16 · see citing works

Synergistic therapeutic strategies for cancer treatment based on nanophototherapy

Liu, S., Song, R., Li, X., & Zhou, F. (2021) · Nanophotonics · doi:10.1515/nanoph-2021-0407 · Cited by 16 · see citing works

Immunotherapies for locally aggressive cancers

Adams, S. C., Nambiar, A., Bressler, E. M., Raut, C. P., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115331 · Cited by 15 · see citing works

Bioengineering nanomaterials for tumor therapy and anti-metastasis

Cheng, J., Pan, Y., Zou, J., Zhang, M., Zhu, Y., Liu, Y., & Chen, X. S. (2024) · Progress in Materials Science · doi:10.1016/j.pmatsci.2024.101375 · Cited by 15 · see citing works

GALNT6 dual regulates innate immunity STING signaling and PD-L1 expression to promote immune evasion in pancreatic ductal adenocarcinoma

Chong, S., Liu, Y., Bian, Z., Hu, D., Guo, S., Dong, C., Zeng, J., Fan, S., & Chen, X. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111942 · Cited by 14 · see citing works

Maleimide functionalized polycaprolactone micelles for glutathione quenching and doxorubicin delivery

Babanyinah, G. K., Bhadran, A., Polara, H., Wang, H., Shah, T. V., Biewer, M. C., & Stefan, M. C. (2024) · Chemical Science · doi:10.1039/d4sc01625d · Cited by 14 · see citing works

Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents

Pla-López, A., Castillo, R., Cejudo-Marín, R., García‐Pedrero, O., Bakir, M., Falomir, E., & Cardá, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137049 · Cited by 14 · see citing works

Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments

Barnwal, A., Das, S., & Bhattacharyya, J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00214 · Cited by 13 · see citing works

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

Kakraba, S., Ayyadevara, S., Mainali, N., Balasubramaniam, M., Bowroju, S., Penthala, N. R., Atluri, R., Barger, S. W., Griffin, S. T., Crooks, P. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16101498 · Cited by 13 · see citing works

Unveiling the landscape of cytokine research in glioma immunotherapy: a scientometrics analysis

Zhang, H., Chen, Y., Jiang, X., Gu, Q., Yao, J., Wang, X., & Wu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1333124 · Cited by 13 · see citing works

Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma

Chacon, A. C., Melucci, A. D., Qin, S. S., & Prieto, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063228 · Cited by 12 · see citing works

Sulfobetaine methacrylate-coated reduced graphene oxide-IR780 hybrid nanosystems for effective cancer photothermal-photodynamic therapy

Melo, B. L., Lima‐Sousa, R., Alves, C. G., Correia, I. J., & de Melo‐Diogo, D. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123552 · Cited by 12 · see citing works

Novel classes of immunotherapy for breast cancer

Hernando‐Calvo, A., Cescon, D. W., & Bedard, P. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06405-2 · Cited by 11 · see citing works

Emerging immunological strategies: recent advances and future directions

Zhao, H., Luo, F., Xue, J., Li, S., & Xu, R. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0886-x · Cited by 11 · see citing works

Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells

Athanasiadis, P., Ravikumar, B., Elliott, R. J. R., Dawson, J. C., Carragher, N. O., Clemons, P. A., Johanssen, T., Ebner, D. V., & Aittokallio, T. A. (2023) · iScience · doi:10.1016/j.isci.2023.107209 · Cited by 10 · see citing works

Small molecule innate immune modulators in cancer therapy

Goswami, A., Goyal, S., Khurana, P., Singh, K., Deb, B., & Kulkarni, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1395655 · Cited by 9 · see citing works

Stimulation and Suppression of the Innate Immune System through Nanotechnology

da Silva, M. C., Rocha, C. V., Bañobre‐López, M., & Gallo, J. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.0c03424 · Cited by 9 · see citing works

A self-delivery photodynamic sensitizer for enhanced DNA damage by PARP inhibition

Kong, R., Li, X., Huang, J., Zhou, X., Deng, F., Li, Y., Liu, L., Li, S., & Cheng, H. B. (2022) · Biomaterials Science · doi:10.1039/d2bm01320g · Cited by 9 · see citing works

Discovery of 3-(Fluoro-imidazolyl)pyridazine Derivatives as Potent STING Agonists with Antitumor Activity

Hou, H., Zhou, J., Sui, Q., Zhang, C., Su, Z., Cui, R., Shan, B., Xu, P., Chen, Z., Jiang, B., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01873 · Cited by 8 · see citing works

Microsystem technologies for accelerating the discovery and translation of immunotherapies

Wang, Z., Liu, C. Y., Chen, K., Song, J. W., & Kelley, S. O. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01268-4 · Cited by 8 · see citing works

Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation

Swetha, K. L., Maravajjala, K. S., Li, S., Singh, M. S., & Roy, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01194-7 · Cited by 8 · see citing works

Discovery of benzofuran-2-carboxylic acid derivatives as lymphoid tyrosine phosphatase (LYP) inhibitors for cancer immunotherapy

Liang, X., Zhao, H., Du, J., Li, X., Li, K., Zhao, Z., Bi, W., Zhang, X., Yu, D., Zhang, J., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115599 · Cited by 8 · see citing works

Neothalfine, a potent natural anti-tumor agent against metastatic colorectal cancer and its primary mechanism

Zhu, Y.-Y., Jin, Q., Chen, S.-S., Jin, D.-N., Wang, Z., He, Y., Chen, H. C., Zhao, Y., Zhao, L., Dai, Z., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115849 · Cited by 8 · see citing works

Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma

Feng, W., He, Z., Shi, L., Zhu, Z., & Ma, H. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10343-7 · Cited by 8 · see citing works

Platinum Twin and Triplet Drugs Improve Chemoimmunotherapy

Hao, Y., Li, R., Pan, W., Tian, S., & Min, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00792 · Cited by 6 · see citing works

Prognostic significance of HSF2BP in lung adenocarcinoma

Huang, Z.-D., Liu, Z., Cheng, X., Han, Z., Li, J., Xia, T., Gao, Y., & Wei, L. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-4935 · Cited by 7 · see citing works

Multiorgan-on-a-chip: an advanced platform for disease modeling, drug toxicity assessment, and therapeutic screening

Qiao, L., Chang, S., Zou, L., Zhang, F., Cui, C., & Huang, N. (2025) · Bio-Design and Manufacturing · doi:10.1631/bdm.2500076 · Cited by 6 · see citing works

Enhancement of Immunotherapies in Head and Neck Cancers Using Biomaterial-Based Treatment Strategies

Sunga, G. M., Hartgerink, J. D., Sikora, A. G., & Young, S. W. (2023) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2023.0090 · Cited by 6 · see citing works

Recent Trends in the Application of Materials for Cancer Therapy and Diagnosis

Bakhshandeh, B., Jahanafrooz, Z., Haghighi, D. M., Rahmani-Kukia, N., Abbasi, A., & Pourramezanali, A. (2023) · Springer eBooks · doi:10.1007/978-981-99-2119-5_12 · Cited by 5 · see citing works

Advanced Therapeutic Approaches in Cancer Therapy

Sobti, R. C., Gosipatala, S. B., Reddy, P., Bisht, N., Kuril, S. R., Madhuri, K., Chand, G., Kaur, T., & Thakur, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-6263-1_79 · Cited by 5 · see citing works

Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for Cancer Immunotherapy

Lin, S., Xiang, N., Liu, W., Wu, D., Chen, Y., Xiong, T., Ge, J., Zhou, W. H., Tian, H., Zhang, K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01036 · Cited by 5 · see citing works

Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review

Gao, X. Y., Hao, W., Wang, Y., Wu, X., Zhu, F., & Zhang, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-14758-w · Cited by 5 · see citing works

Pyrimidyn‐Based Dynamin Inhibitors as Novel Cytotoxic Agents

Odell, L. R., Chau, N., Russell, C. C., Young, K. A., Gilbert, J., Robinson, P. J., Sakoff, J. A., & McCluskey, A. (2021) · ChemMedChem · doi:10.1002/cmdc.202100560 · Cited by 5 · see citing works

FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells.

Chung, Y. M., Tsai, W.-B., Khan, P. P., Ma, J., Berek, J. S., Larrick, J. W., & Hu, M. C. ‐. (2022) · PubMed Central · Cited by 5 · see citing works

Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein I through Molecular Dynamics with Probes and Virtual Screening

Andrade, L., Albuquerque, A., Santos-Costa, A. H., VASCONCELOS, D. B., Savino, W., Sartori, G., & da Silva, J. H. M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01122 · Cited by 5 · see citing works

Distepharinamide, a novel dimeric proaporphine alkaloid from Diploclisia glaucescens, inhibits the differentiation and proliferative expansion of CD4+Foxp3+ regulatory T cells

Chen, F., Geng, C., Chou, C., Zheng, J.-B., Yang, Y., Wang, Y., Li, T.-Z., Li, P., Chen, J., & Chen, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154482 · Cited by 5 · see citing works

PROTAC-powered synergistic tumor therapy

Wang, X., Zou, J., Tao, Y., Zhou, Z., Bian, C., Mao, Z., & Liu, Z. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118678 · Cited by 4 · see citing works

RORγt agonist LYC-55716 potentiates IFN-α’s efficacy in hepatocellular carcinoma through enhancing cytotoxicity of Tc17 cells and infiltration of CD8+ T cells

Wang, H., Zhang, G., Zhao, C., Xue, Y., Zhu, D., & Chang, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116963 · Cited by 4 · see citing works

ISGylation prevents autophagic degradation of STING and promotes antitumor immunity in lung cancer

Cao, D., Bin, H., Fu, X., Liu, M., Niu, X., Zhai, H., & Huang, H. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08527-1 · Cited by 4 · see citing works

A novel pyroptosis-related indicator of immune infiltration features and prognosis in breast cancer

Wang, C., Zhang, L., Ren, L., Zhang, G., Wan, A., Xiong, S., Tian, H., Peng, Z., Zhao, T., Gao, P., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961500 · Cited by 4 · see citing works

Injectable polydopamine/curcumin dual-modified polylactic acid/polycaprolactone coaxial staple fibers for chronotropic treatment of oral squamous cell carcinoma

Chen, X., Sun, L., Ning, Y., Zhou, L., Guo, Y., Xu, R., & Wu, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139094 · Cited by 4 · see citing works

Challenges and Future Opportunities of Nanomedicine in Cancer Therapy

Narayan, S. (2021) · Springer eBooks · doi:10.1007/978-981-15-7564-8_10 · Cited by 4 · see citing works

Exploring Thiazolopyridine AV25R: Unraveling of Biological Activities, Selective Anti-Cancer Properties and In Silico Target and Binding Prediction in Hematological Neoplasms

Ladwig, A., Gupta, S. K., Ehlers, P., Sekora, A., Alammar, M., Koczan, D., Olaf Wolkenhauer, A., Junghanß, C., Langer, P., & Escobar, H. M. (2023) · Molecules · doi:10.3390/molecules28248120 · Cited by 3 · see citing works

Emerging nanomaterials for cancer immunotherapy

Pandian, S. R. K., Rencilin, C. F., & Sundar, K. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00043 · Cited by 3 · see citing works

Proof of concept: Pull down assay using bovine serum albumin and an immunomodulator small molecule

Tabana, Y., Lin, C. C., Babu, D., Piragasam, R. S., Ponich, A. A., Moon, T. C., Siraki, A. G., Elahi, S., Fahlman, R. P., West, F. G., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21408 · Cited by 2 · see citing works

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors for Treating Cancer

Sabnis, R. W. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00393 · Cited by 2 · see citing works

pH-responsive polymer-based biomacromolecule nanosponges as biodegradable carriers for DOX deliveryPreprint

Nia, M. H., Ashkar, S., Munguia-López, J. G., Kinsella, J. M., & van de Ven, T. G. M. (2021) · ChemRxiv · doi:10.26434/chemrxiv-2021-43zr3 · Cited by 2 · see citing works

Imidazoloquinoline optical isomers as TLR7 selective agonists promote macrophage activation for cancer immunotherapy

Pan, Y., Fu, Q., Yang, M., Chen, Z., & Cheng, K. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109041 · Cited by 1 · see citing works

Chemical reprogramming regulates Tip60 expression to improve cleavage rates in somatic cell nuclear transfer reconstituted embryos of cashmere goats

Zhe, X.-S., Zhang, L., Ding, R., Ma, H.-R., Zhang, Y., Hao, F., Liu, D.-J., & Li, Y. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1720533 · Cited by 2 · see citing works

Advanced engineering of hydrogel platforms for cancer immunotherapy via distinct administration routes

Mo, X. W., Min, D. K., & Kim, J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115036 · Cited by 1 · see citing works

Design and Synthesis of Tri-substituted Imidazole Derivatives as CD73 Inhibitors for Their Anticancer Activity

Ghara, A., Andhale, G. S., Matada, G. S. P., & Dhiwar, P. S. (2021) · Letters in Drug Design & Discovery · doi:10.2174/1570180818666210604113849 · Cited by 1 · see citing works

Delivery strategies for ex vivo and in vivo T-cell reprogramming

Ben‐Akiva, E., Karlsson, J. E., Tzeng, S. Y., Yu, H., & Green, J. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00002-6 · Cited by 1 · see citing works

Stimuli-responsive drug delivery systems for cancer immunotherapy

Ding, Y., & Hu, Q. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824456-2.00014-x · Cited by 1 · see citing works

Role of small molecule-based drugs in cancer immunotherapy

Shah, U., Patel, M., Patel, A., Shah, P., Dwivedi, A. R., & Maheshwari, R. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00014-x

Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators

Weinmann, H. (2016) · ChemMedChem · doi:10.1002/cmdc.201500566 · Cited by 122 · see citing works

Small-molecule agents for cancer immunotherapy

Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71 · see citing works

Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs

Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189170 · Cited by 22 · see citing works

Research Advances on Small Molecule Targets for Tumor Immunotherapy

Lie, L., Meng, Y. G., & Shi, J. (2019) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3971/j.issn.1000-8578.2019.19.0094